Wockardt gets US nod for Tamsulosin capsules
September 29th, 2009 - 10:06 pm ICT by IANSChennai, Sep 29 (IANS) Pharma major Wockhardt Tuesday got the US Food and Drug Administration’s (USFDA) tentative approval for marketing Tamsulosin Hydrochloride capsules.
Tamsulosin is being used for treating non-cancerous enlargement of prostate, technically called benign prostatic hyperplasia.
Tamsulosin is the generic name for the brand Flomax, developed by Japanese drug major Astellas and marketed in the US by Boehringer Ingelheim.
The patent on this product will expire April 27, 2010 and Wockhardt will launch the product immediately thereafter, said a company statement.
No other company has got the USFDA sanction for the Tamsulosin capsule of 0.4mg strength, a company spokesperson claimed.
He said the total market for Tamsulosin capsules in the US is about $1,650 million.
- Orchid gets tentative FDA approval for Alzheimer's drug - Jan 08, 2010
- Ranbaxy settles issue with US health regulator - Dec 21, 2011
- Combo therapy for enlarged prostate more effective - Mar 03, 2010
- Dr Reddy's launches anti-asthma tablets in US - Nov 20, 2010
- Orchid Chemicals signs out-licensing deal with Alvogen - May 05, 2010
- Hamster study shows cholesterol-lowering drug shrinks enlarged prostates - Oct 22, 2010
- Core Gestra bags pharma excellence award - May 26, 2011
- Ranbaxy approved to make first generic version of Lipitor - Dec 01, 2011
- Orchid Chemical to acquire US marketing company - Jun 10, 2010
- Indian drug major Sun Pharma takes control of Israeli Taro - Sep 22, 2010
- FDA Not Impressed By The First 'Female Viagra' - Jun 17, 2010
- Orchid Chemicals' plant shut on pollution concerns - Jul 11, 2011
- Aurobindo Pharma gets US approval for HIV tablets - Sep 17, 2008
- US health regulator approves Chennai drug plant - Jun 22, 2011
- Surgery for benign prostatic hyperplasia offers more relief than drug therapy - May 30, 2010
Tags: astellas, benign prostatic hyperplasia, boehringer ingelheim, company spokesperson, flomax, food and drug, food and drug administration, generic name, marketing, patent, sanction, tamsulosin hydrochloride, tentative approval, us food and drug administration, wockhardt